Don't Get Stuck on the Shoulder: Radiation Oncologists Should Get Into the CAR With T-Cell Therapies

Within the last 2 years, the U.S. Food and Drug Administration approved 2 chimeric antigen receptor (CAR) T-cell therapies for relapsed/refractory diffuse large B-cell lymphoma, high-grade B cell lymphoma, and transformed follicular lymphoma ” axicabtagene ciloleucel or “axi-cel” (Yescarta, Kite Pharma) and tisagenlecleucel or “tisa-cel” (Kymriah, Novartis). Both products target CD19, a ubiquitous surface antigen on mature and malignant B-cells, but these chimeric receptors differ in their costimulatory domains (eg, CD28 for a xi-cel and 41-BB for tisa-cel), which affects pharmacokinetics, CAR T-cell persistence, and toxicity.
Source: International Journal of Radiation Oncology * Biology * Physics - Category: Radiology Authors: Tags: Clinical Investigation Source Type: research